US EditionPublished • loading... • Updated
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
- On Friday, AstraZeneca signed a deal securing global rights, outside Greater China, to CSPC Pharmaceutical Group's once-monthly injectable weight-management portfolio covering eight obesity and diabetes programmes with $17.2 billion in potential milestone payments.
- On Thursday, AstraZeneca pledged a $15 billion investment programme through 2030 in China, coinciding with UK Prime Minister Sir Keir Starmer's visit, highlighting trade and diplomatic links.
- Paying $1.2 billion upfront, AstraZeneca secured access to CSPC Pharmaceutical Group's LiquidGel sustained-release delivery technology, AI-powered peptide drug discovery programme, and clinical-ready SYH2082, a monthly long-acting GLP-1/GIP agonist.
- Under the agreement, AstraZeneca will handle development and commercialization outside Greater China while CSPC Pharmaceutical Group retains local rights; a Hong Kong Stock Exchange filing shows CSPC could receive $3.5 billion in R&D milestone payments and up to $13.8 billion for commercial objectives plus royalties.
- The deal positions AstraZeneca as still behind Novo Nordisk and Eli Lilly in obesity, while analysts forecast the obesity market could top $100 billion by 2030 and feed AZ's $80 billion, 20-medicine 2030 ambitions.
Insights by Ground AI
17 Articles
17 Articles
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. The post AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds appeared first on MedCity News.
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.
Coverage Details
Total News Sources17
Leaning Left2Leaning Right0Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 29%
C 71%
Factuality
To view factuality data please Upgrade to Premium
